NO20042187L - Antranilsyreamider og deres anvendelse som VEGF-reseptor tyrorsinkinaseinhibitorer. - Google Patents

Antranilsyreamider og deres anvendelse som VEGF-reseptor tyrorsinkinaseinhibitorer.

Info

Publication number: NO20042187L
Authority: NO; Norway
Prior art keywords: anthranilic acid; treatment; acid amides; thyrorsin; kinase inhibitors
Prior art date: 2001-11-08

Application number

NO20042187A

Other languages

English (en)

Other versions

NO327231B1 (no

Inventor

Guido Bold

Pascal Furet

Paul William Manley

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-11-08

Filing date

2004-05-26

Publication date

2004-05-26

2004-05-26 Application filed by Novartis Ag filed Critical Novartis Ag

2004-05-26 Publication of NO20042187L publication Critical patent/NO20042187L/no

2009-05-18 Publication of NO327231B1 publication Critical patent/NO327231B1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/63—One oxygen atom
- C07D213/64—One oxygen atom attached in position 2 or 6
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Public Health (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Vascular Medicine (AREA)
Heart & Thoracic Surgery (AREA)
Rheumatology (AREA)
Pulmonology (AREA)
Cardiology (AREA)
Dermatology (AREA)
Ophthalmology & Optometry (AREA)
Reproductive Health (AREA)
Immunology (AREA)
Orthopedic Medicine & Surgery (AREA)
Endocrinology (AREA)
Physical Education & Sports Medicine (AREA)
Epidemiology (AREA)
Hematology (AREA)
Oncology (AREA)
Pain & Pain Management (AREA)
Urology & Nephrology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

NO20042187A 2001-11-08 2004-05-26 Antranilsyreamider, farmasoytske preparat, anvendelser samt fremgangsmate for fremstilling NO327231B1 (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0126902.6A GB0126902D0 (en)	2001-11-08	2001-11-08	Organic compounds
PCT/EP2002/012444 WO2003040102A1 (en)	2001-11-08	2002-11-07	Anthranilic acid amides and their use as vegf receptor tyrosine kinase inhibitors

Publications (2)

Publication Number	Publication Date
NO20042187L true NO20042187L (no)	2004-05-26
NO327231B1 NO327231B1 (no)	2009-05-18

Family

ID=9925448

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20042187A NO327231B1 (no)	2001-11-08	2004-05-26	Antranilsyreamider, farmasoytske preparat, anvendelser samt fremgangsmate for fremstilling

Country Status (28)

Country	Link
US (2)	US7091224B2 (no)
EP (1)	EP1446382B1 (no)
JP (1)	JP2005511602A (no)
KR (1)	KR100602977B1 (no)
CN (1)	CN1300113C (no)
AT (1)	ATE496889T1 (no)
AU (1)	AU2002351909B2 (no)
BR (1)	BR0213970A (no)
CA (1)	CA2463968C (no)
CO (1)	CO5580823A2 (no)
DE (1)	DE60239073D1 (no)
ES (1)	ES2360283T3 (no)
GB (1)	GB0126902D0 (no)
HR (1)	HRP20040411A2 (no)
IL (1)	IL161747A0 (no)
MX (1)	MXPA04004391A (no)
NO (1)	NO327231B1 (no)
NZ (1)	NZ532590A (no)
PE (1)	PE20030714A1 (no)
PL (1)	PL368416A1 (no)
PT (1)	PT1446382E (no)
RU (1)	RU2318811C2 (no)
SA (1)	SA02230412B1 (no)
TW (1)	TWI260222B (no)
UA (1)	UA77446C2 (no)
WO (1)	WO2003040102A1 (no)
YU (1)	YU36004A (no)
ZA (1)	ZA200402940B (no)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7307088B2 (en) *	2002-07-09	2007-12-11	Amgen Inc.	Substituted anthranilic amide derivatives and methods of use
US7615565B2 (en)	2002-07-31	2009-11-10	Bayer Schering Pharma Aktiengesellschaft	VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
GB0229022D0 (en) *	2002-12-12	2003-01-15	Novartis Ag	Organic Compounds
DE10327719A1 (de) *	2003-06-13	2005-01-20	Schering Ag	VEGFR-2 und VEGFR-3 Inhibitorische Anthranylamidpyridone
US7202260B2 (en)	2003-06-13	2007-04-10	Schering Ag	VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridones
US7129252B2 (en) *	2003-06-16	2006-10-31	Guoqing P Chen	Six membered amino-amide derivatives an angiogenisis inhibitors
UA89035C2 (ru)	2003-12-03	2009-12-25	Лео Фарма А/С	Эфиры гидроксамовых кислот и их фармацевтическое применение
EP1568368A1 (en) *	2004-02-26	2005-08-31	Schering Aktiengesellschaft	Pharmaceutical combination comprising a CDK inhibitor and a VEGF receptor inhibitor
EP1655295A1 (en)	2004-11-03	2006-05-10	Schering Aktiengesellschaft	Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en)	2004-11-03	2011-03-15	Bayer Schering Pharma Ag	Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1657241A1 (en)	2004-11-03	2006-05-17	Schering Aktiengesellschaft	Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
CA2588633A1 (en)	2004-12-07	2006-06-15	Toyama Chemical Co., Ltd.	Novel anthranilic acid derivative or salt thereof
US7547782B2 (en)	2005-09-30	2009-06-16	Bristol-Myers Squibb Company	Met kinase inhibitors
CN101265274B (zh) *	2007-02-16	2013-09-04	中国医学科学院药物研究所	嘧啶噻唑胺衍生物、及其制法和药物组合物与用途
PA8840701A1 (es)	2008-08-27	2010-04-21	Leo Pharma As	NUEVO RECEPTOR VEGF-2 e INHIBIDORES DE PROTEÍNAS TIROSINA QUINASA Y SU USO FARMACÉUTICO DE LOS MISMOS
JO3265B1 (ar)	2008-12-09	2018-09-16	Novartis Ag	مثبطات بيريديلوكسى اندولات vegf-r2 واستخدامها لعلاج المرض
GB201322538D0 (en)	2013-06-21	2014-02-05	Immusmol Sas	Method for detecting small molecules in a sample
CN107954893A (zh) *	2017-11-28	2018-04-24	兰州纬寰生物科技有限公司	邻氨基苯甲酰胺衍生物及制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CZ59398A3 (cs) *	1996-06-29	1998-07-15	Samjin Pharmaceutical Co., Ltd.	Piperazinové deriváty a způsob jejich přípravy
GB9824579D0 (en) *	1998-11-10	1999-01-06	Novartis Ag	Organic compounds
UA71587C2 (uk) *	1998-11-10	2004-12-15	Шерінг Акцієнгезелльшафт	Аміди антранілової кислоти та їхнє застосування як лікарських засобів

2001
- 2001-11-08 GB GBGB0126902.6A patent/GB0126902D0/en not_active Ceased
2002
- 2002-07-11 UA UA20040403226A patent/UA77446C2/uk unknown
- 2002-11-02 SA SA02230412A patent/SA02230412B1/ar unknown
- 2002-11-06 TW TW091132669A patent/TWI260222B/zh active
- 2002-11-06 PE PE2002001080A patent/PE20030714A1/es not_active Application Discontinuation
- 2002-11-07 ES ES02787595T patent/ES2360283T3/es not_active Expired - Lifetime
- 2002-11-07 HR HR20040411A patent/HRP20040411A2/hr not_active Application Discontinuation
- 2002-11-07 EP EP02787595A patent/EP1446382B1/en not_active Expired - Lifetime
- 2002-11-07 DE DE60239073T patent/DE60239073D1/de not_active Expired - Lifetime
- 2002-11-07 KR KR1020047007040A patent/KR100602977B1/ko not_active Expired - Fee Related
- 2002-11-07 AT AT02787595T patent/ATE496889T1/de active
- 2002-11-07 PT PT02787595T patent/PT1446382E/pt unknown
- 2002-11-07 CA CA2463968A patent/CA2463968C/en not_active Expired - Fee Related
- 2002-11-07 CN CNB028222091A patent/CN1300113C/zh not_active Expired - Fee Related
- 2002-11-07 MX MXPA04004391A patent/MXPA04004391A/es active IP Right Grant
- 2002-11-07 RU RU2004117543/04A patent/RU2318811C2/ru not_active IP Right Cessation
- 2002-11-07 AU AU2002351909A patent/AU2002351909B2/en not_active Ceased
- 2002-11-07 YU YU36004A patent/YU36004A/sh unknown
- 2002-11-07 WO PCT/EP2002/012444 patent/WO2003040102A1/en not_active Ceased
- 2002-11-07 IL IL16174702A patent/IL161747A0/xx unknown
- 2002-11-07 US US10/494,591 patent/US7091224B2/en not_active Expired - Fee Related
- 2002-11-07 JP JP2003542148A patent/JP2005511602A/ja active Pending
- 2002-11-07 PL PL02368416A patent/PL368416A1/xx not_active Application Discontinuation
- 2002-11-07 NZ NZ532590A patent/NZ532590A/en not_active IP Right Cessation
- 2002-11-07 BR BR0213970-7A patent/BR0213970A/pt not_active IP Right Cessation
2004
- 2004-04-19 ZA ZA200402940A patent/ZA200402940B/en unknown
- 2004-05-12 CO CO04043909A patent/CO5580823A2/es not_active Application Discontinuation
- 2004-05-26 NO NO20042187A patent/NO327231B1/no not_active IP Right Cessation
2006
- 2006-03-14 US US11/374,720 patent/US7482369B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
GB0126902D0 (en)	2002-01-02
KR100602977B1 (ko)	2006-07-20
RU2318811C2 (ru)	2008-03-10
ES2360283T3 (es)	2011-06-02
TW200300087A (en)	2003-05-16
CN1300113C (zh)	2007-02-14
US20060178409A1 (en)	2006-08-10
TWI260222B (en)	2006-08-21
AU2002351909B2 (en)	2007-04-26
WO2003040102A1 (en)	2003-05-15
EP1446382A1 (en)	2004-08-18
CA2463968A1 (en)	2003-05-15
RU2004117543A (ru)	2006-01-10
YU36004A (sh)	2006-08-17
HRP20040411A2 (en)	2005-04-30
DE60239073D1 (de)	2011-03-10
BR0213970A (pt)	2004-08-31
PL368416A1 (en)	2005-03-21
PE20030714A1 (es)	2003-10-13
JP2005511602A (ja)	2005-04-28
US7482369B2 (en)	2009-01-27
ATE496889T1 (de)	2011-02-15
NZ532590A (en)	2005-12-23
ZA200402940B (en)	2005-02-10
KR20050044382A (ko)	2005-05-12
UA77446C2 (en)	2006-12-15
EP1446382B1 (en)	2011-01-26
PT1446382E (pt)	2011-05-03
US20050096356A1 (en)	2005-05-05
US7091224B2 (en)	2006-08-15
CN1585750A (zh)	2005-02-23
CA2463968C (en)	2011-02-22
CO5580823A2 (es)	2005-11-30
IL161747A0 (en)	2005-11-20
SA02230412B1 (ar)	2007-07-31
MXPA04004391A (es)	2005-12-12
NO327231B1 (no)	2009-05-18

Publication	Publication Date	Title
NO20042187L (no)	2004-05-26	Antranilsyreamider og deres anvendelse som VEGF-reseptor tyrorsinkinaseinhibitorer.
EA200970611A1 (ru)	2009-12-30	Замещенные пиразолохиназолиновые производные, способ их получения и их применение в качестве ингибиторов киназы
BR0009507A (pt)	2002-01-15	Derivados de ftalazina para o tratamento de doenças inflamatórias
NO20073465L (no)	2002-12-12	Benzotiazol-derivater
MXPA01004256A (es)	2003-06-06	N-arilamidas del acido antranilico y del acido tioantranilico.
NO20034148L (no)	2003-11-14	Triazaspiro[5.5]undekanderivater og legemidler inneholdende disse som den aktive bestanddel
MX2008013836A (es)	2008-11-10	Derivados de 2-piridona para el tratamiento de enfermedades o condiciones en las cuales es benefica la inhibicion de la actividad de elastasa de neutrofilos.
MX2007000028A (es)	2007-07-20	Derivados de nicotinamida y su uso como agentes terapeuticos.
BRPI0418074B8 (pt)	2021-05-25	derivado de amida, composição farmacêutica, inibidor da tirosina cinase bcr-abl e agentes terapêuticos
BRPI0413438A (pt)	2006-10-17	derivados de pirimidilpirrol ativos como inibidores de cinase
BRPI0415826A (pt)	2007-01-02	derivados de ceto-oxadiazol como inibidores de catepsina
EA200601418A1 (ru)	2006-12-29	ПРОИЗВОДНЫЕ 1Н-ТИЕНО [2,3-с] ПИРАЗОЛА, ПРЕДНАЗНАЧЕННЫЕ ДЛЯ ИСПОЛЬЗОВАНИЯ В КАЧЕСТВЕ ИНГИБИТОРОВ КИНАЗЫ
DE60108626D1 (de)	2005-03-03	Verwendung von 5-thio, sulfinyl- und sulfonylpyrazolo 3,4-b] pyridinen als cyclin-abhängige kinase-hemmer
NO20052698L (no)	2005-06-06	4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gasatrintestinale lidelser.
ATE366107T1 (de)	2007-07-15	Verwendung von sulfodehydroabietinsäure zur behandlung entzündlicher darmerkrankungen
MY136322A (en)	2008-09-30	Anthranilic acid amides and pharmaceutical use thereof
NO20052699L (no)	2005-06-06	4(fenylpiperazinyl-metyl)benzamid-derivater og deres anvendelse ved behandling av smerte og gastrointestinale lidelser.
MXPA05014143A (es)	2006-02-24	Derivados de cumarina para el tratamiento de trastornos oftalmicos.
ECSP045092A (es)	2004-06-28	Amidas de acido antranilico y su uso como inhibidores de tirosina-cinasa del receptor de vegf
BR0317292A (pt)	2005-11-08	Derivados de amida de ácido antranìlico e seu uso farmacêutico
TH88080A (th)	2008-01-10	แอนทรานิลิกแอซิดเอไมด์และการใช้งานทางเภสัชกรรมของมัน
UY27534A1 (es)	2003-07-31	Amidas de ácido antranílico y uso farmacológico de las mismas.
TH88080B (th)	2008-01-10	"แอนทรานิลิกแอซิดเอไมด์และการใช้งานทางเภสัชกรรมของมัน"
TH64488A (th)	2004-10-05	แอนทรานิลิกแอซิดเอไมด์และการใช้งานทางเภสัชกรรมของมัน
TH51069A3 (th)	2002-05-22	อนุพันธ์ 2,4-ไดซับสทิทิวเทด ไทรแอซีน

Legal Events

Date	Code	Title	Description
2012-06-25	MM1K	Lapsed by not paying the annual fees